Home

Deliv­er­ing nucle­ic acid med­i­cines from promise to performance

Nucle­ic acids car­ry the code. 
Deliv­ery deter­mines how far they go.

Your cargo is ready. Is your delivery? 
Mirai Bio de-risks our partners’ path from concept to clinic.

One inte­grat­ed plat­form to solve delivery

Mirai brings togeth­er car­go design, LNP chem­istry, in vivo eval­u­a­tion, and man­u­fac­tura­bil­i­ty in a sin­gle devel­op­ment loop, turn­ing frag­ment­ed devel­op­ment into faster, more trans­lat­able progress.

Mirai’s Integrated Platform

Deliv­ery makes the medicine

Mirai tai­lors the LNP sys­tem to the car­go, tar­get biol­o­gy, route of admin­is­tra­tion, and devel­op­ment path, cre­at­ing a deliv­ery solu­tion built around the needs of the pro­gram from the start.

Program-specific LNP design

Expand­ing where nucle­ic acid med­i­cines can go

Mirai com­bines pro­pri­etary lipid chem­istry, cell-spe­cif­ic tar­get­ing, and in vivo opti­miza­tion to cre­ate deliv­ery sys­tems with the poten­cy, speci­fici­ty, selec­tiv­i­ty, tol­er­a­bil­i­ty, and trans­la­tion­al poten­tial required to reach pre­vi­ous­ly inac­ces­si­ble tis­sues and unlock new ther­a­peu­tic frontiers.

Targeted delivery beyond the liver

Built for pro­grams that require more from delivery

Mirai works with inno­va­tors across mRNA, tRNA, siR­NA, self-ampli­fy­ing RNA, cir­cu­lar RNA, gene-edit­ing car­go, DNA-based modal­i­ties, and relat­ed approach­es to solve deliv­ery and devel­op­ment chal­lenges that stan­dard mod­els do not address.

PARTNER WITH MIRAI

Inno­va­tion at every step.

Design for the end from the beginning.

  1. 1

    Define the destination

    Align cargo, target biology, cell or tissue, route of administration, and development goal to establish the right delivery strategy at the start. 

  2. 2

    Optimize in vivo

    Generate high-quality in vivo data and use ML-guided optimization to improve potency, selectivity, liver detargeting, and tolerability.

  3. 3

    Build for translation

    Integrate process development, analytics, scale-up, and manufacturing planning early to support continued advancement.

A plat­form for trans­lat­ing at speed and scale

Mirai com­bines pro­pri­etary in vivo data with machine learn­ing to explore the LNP design space, iden­ti­fy high-per­form­ing can­di­dates, and con­tin­u­ous­ly improve deliv­ery performance.

Built to Translate

Mov­ing deliv­ery for­ward faster

  • 4x Faster dis­cov­ery-to-NHP devel­op­ment com­pared with indus­try benchmarks

  • 5,000+ Ion­iz­able lipid library backed by durable IP

  • 400+ Pro­pri­etary ion­iz­able lipids screened in vivo

  • 30+ Ion­iz­able lipids out­per­form­ing com­mer­cial standards

  • 10+ Extra hepat­ic tar­gets reached

Expe­ri­ence across deliv­ery, devel­op­ment, and translation

Mirai brings togeth­er exper­tise in lipid chem­istry, in vivo biol­o­gy, machine learn­ing, tech­ni­cal devel­op­ment, and nucle­ic acid process devel­op­ment to help part­ners advance more trans­lat­able medicines.

Leadership
A man and woman working in the Mirai lab.

Join us

Let’s define the future of genetic medicine together.